SI2331538T1 - Kristalinične oblike 2-tiazolil-4-kinolinil-oksi derivata, učinkovitega inhibitorja HCV - Google Patents

Kristalinične oblike 2-tiazolil-4-kinolinil-oksi derivata, učinkovitega inhibitorja HCV

Info

Publication number: SI2331538T1
Authority: SI; Slovenia
Prior art keywords: quinolinyl; thiazolyl; crystalline forms; hcv inhibitor; oxy derivative
Prior art date: 2008-09-16

Application number

SI200930919T

Other languages

English (en)

Inventor

Thilo Berkenbusch

Carl Alan Busacca

Burkhard Jaeger

Richard J. Varsolona

Original Assignee

Boehringer Ingelheim International Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-16

Filing date

2009-09-14

Publication date

2014-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41268627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2331538(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-14 Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh

2014-06-30 Publication of SI2331538T1 publication Critical patent/SI2331538T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SI200930919T 2008-09-16 2009-09-14 Kristalinične oblike 2-tiazolil-4-kinolinil-oksi derivata, učinkovitega inhibitorja HCV SI2331538T1 (sl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US9729108P	2008-09-16	2008-09-16
US15082609P	2009-03-09	2009-03-09
PCT/US2009/056772 WO2010033444A1 (en)	2008-09-16	2009-09-14	Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor
EP09792493.0A EP2331538B1 (en)	2008-09-16	2009-09-14	Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor

Publications (1)

Publication Number	Publication Date
SI2331538T1 true SI2331538T1 (sl)	2014-06-30

Family

ID=41268627

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200930919T SI2331538T1 (sl)	2008-09-16	2009-09-14	Kristalinične oblike 2-tiazolil-4-kinolinil-oksi derivata, učinkovitega inhibitorja HCV

Country Status (34)

Country	Link
US (2)	US8232293B2 (sl)
EP (2)	EP2687526A1 (sl)
JP (2)	JP5520301B2 (sl)
KR (1)	KR101653550B1 (sl)
CN (1)	CN102159571B (sl)
AR (1)	AR073298A1 (sl)
AU (1)	AU2009293494B2 (sl)
BR (1)	BRPI0918513A2 (sl)
CA (1)	CA2737055C (sl)
CL (1)	CL2011000558A1 (sl)
CO (1)	CO6351741A2 (sl)
CY (1)	CY1115253T1 (sl)
DK (1)	DK2331538T3 (sl)
EA (1)	EA018603B1 (sl)
EC (1)	ECSP11010878A (sl)
ES (1)	ES2474992T3 (sl)
HK (1)	HK1156624A1 (sl)
HR (1)	HRP20140666T1 (sl)
IL (1)	IL210345A (sl)
MA (1)	MA32633B1 (sl)
ME (1)	ME01831B (sl)
MX (1)	MX2011002828A (sl)
MY (1)	MY153093A (sl)
NZ (2)	NZ602163A (sl)
PE (2)	PE20130307A1 (sl)
PL (1)	PL2331538T3 (sl)
PT (1)	PT2331538E (sl)
RS (1)	RS53292B (sl)
SG (1)	SG189740A1 (sl)
SI (1)	SI2331538T1 (sl)
TW (1)	TWI471323B (sl)
UY (1)	UY32119A (sl)
WO (1)	WO2010033444A1 (sl)
ZA (1)	ZA201100096B (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY32099A (es)	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
SI2331538T1 (sl) *	2008-09-16	2014-06-30	Boehringer Ingelheim International Gmbh	Kristalinične oblike 2-tiazolil-4-kinolinil-oksi derivata, učinkovitega inhibitorja HCV
EP2337583A1 (en)	2008-09-17	2011-06-29	Boehringer Ingelheim International GmbH	Combination of hcv ns3 protease inhibitor with interferon and ribavirin
WO2010105181A1 (en) *	2009-03-13	2010-09-16	University Of Toledo	Minimally invasive collapsible cage
US20120142929A1 (en) *	2009-03-19	2012-06-07	Boehringer Ingelheim International Gmbh	Process for preparing sulfonyl quinolines
EP2427434B1 (en)	2009-05-05	2017-05-31	Boehringer Ingelheim International GmbH	Process for preparing bromo-substituted quinolines
EA023433B1 (ru)	2009-07-07	2016-06-30	Бёрингер Ингельхайм Интернациональ Гмбх	Фармацевтическая композиция ингибитора протеазы вируса гепатита c
US8822496B2 (en)	2009-10-30	2014-09-02	Boehringer Ingelheim International Gmbh	Dosage regimens for HCV combination therapy
US8530497B2 (en)	2010-03-11	2013-09-10	Boehringer Ingelheim International Gmbh	Crystalline salts of a potent HCV inhibitor
KR20130116245A (ko)	2010-09-30	2013-10-23	베링거 인겔하임 인터내셔날 게엠베하	Ｈｃｖ 감염 치료용 병용 요법
CN103534256B (zh)	2010-12-30	2016-08-10	益安药业	大环丙型肝炎丝氨酸蛋白酶抑制剂
EP2658858A4 (en)	2010-12-30	2014-06-25	Enanta Pharm Inc	MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
EA201490837A1 (ru)	2011-10-21	2014-11-28	Эббви Инк.	Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
DE112012003457T5 (de)	2011-10-21	2015-03-12	Abbvie Inc.	Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
SG11201404042VA (en)	2012-01-12	2014-08-28	Boehringer Ingelheim Int	Stabilized pharmaceutical formulations of a potent hcv inhibitor
JP2015509980A (ja)	2012-03-14	2015-04-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013147750A1 (en)	2012-03-27	2013-10-03	Boehringer Ingelheim International Gmbh	Oral combination therapy for treating hcv infection in specific patient sub-population
WO2013147749A1 (en)	2012-03-27	2013-10-03	Boehringer Ingelheim International Gmbh	Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013143581A1 (en)	2012-03-28	2013-10-03	Boehringer Ingelheim International Gmbh	Combination therapy for treating hcv infection in specific patient subgenotype sub-population
UA119315C2 (uk)	2012-07-03	2019-06-10	Гіліад Фармассет Елелсі	Інгібітори вірусу гепатиту с
WO2014138374A1 (en)	2013-03-08	2014-09-12	Boehringer Ingelheim International Gmbh	Oral combination therapy for treating hcv infection in specific patient sub-population
EP2968154B1 (en) *	2013-03-15	2020-06-17	Boehringer Ingelheim International GmbH	Solid oral dosage formulation of hcv inhibitor in the amorphous state
CN105073758B (zh)	2013-03-15	2017-08-11	吉利德科学公司	丙型肝炎病毒抑制剂
EP3089757A1 (en)	2014-01-03	2016-11-09	AbbVie Inc.	Solid antiviral dosage forms
EP3448392A4 (en)	2016-04-28	2020-01-15	Emory University	ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
WO2022107182A1 (en) *	2020-11-18	2022-05-27	University Of Petra	A composition of fentanyl and fatty acids, and a method of preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1033128E (pt)	1993-09-28	2008-08-08	Scherer Gmbh R P	Fabrico de cápsulas de gelatina mole
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
AR022061A1 (es)	1998-08-10	2002-09-04	Boehringer Ingelheim Ca Ltd	Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6608027B1 (en)	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en)	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SK9742002A3 (en) *	2000-01-07	2003-02-04	Transform Pharmaceuticals Inc	High-throughput formation, identification, and analysis of diverse solid-forms
UY28240A1 (es) *	2003-03-27	2004-11-08	Boehringer Ingelheim Pharma	Fases cristalinas de un potente inhibidor de la hcv
MY143076A (en) *	2003-05-21	2011-02-28	Boehringer Ingelheim Int	Hepatitis c inhibitors compounds
JP5156374B2 (ja)	2004-05-25	2013-03-06	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	非環式ｈｃｖプロテアーゼインヒビターの調製方法
SI2331538T1 (sl) *	2008-09-16	2014-06-30	Boehringer Ingelheim International Gmbh	Kristalinične oblike 2-tiazolil-4-kinolinil-oksi derivata, učinkovitega inhibitorja HCV
US8530497B2 (en)	2010-03-11	2013-09-10	Boehringer Ingelheim International Gmbh	Crystalline salts of a potent HCV inhibitor

2009
- 2009-09-14 SI SI200930919T patent/SI2331538T1/sl unknown
- 2009-09-14 PL PL09792493T patent/PL2331538T3/pl unknown
- 2009-09-14 BR BRPI0918513A patent/BRPI0918513A2/pt not_active Application Discontinuation
- 2009-09-14 PE PE2012002419A patent/PE20130307A1/es active IP Right Grant
- 2009-09-14 AU AU2009293494A patent/AU2009293494B2/en not_active Ceased
- 2009-09-14 NZ NZ602163A patent/NZ602163A/xx not_active IP Right Cessation
- 2009-09-14 ME MEP-2014-43A patent/ME01831B/me unknown
- 2009-09-14 EP EP13188665.7A patent/EP2687526A1/en not_active Withdrawn
- 2009-09-14 JP JP2011527015A patent/JP5520301B2/ja active Active
- 2009-09-14 RS RS20140230A patent/RS53292B/en unknown
- 2009-09-14 CN CN200980136131.XA patent/CN102159571B/zh not_active Expired - Fee Related
- 2009-09-14 WO PCT/US2009/056772 patent/WO2010033444A1/en active Application Filing
- 2009-09-14 NZ NZ591013A patent/NZ591013A/xx not_active IP Right Cessation
- 2009-09-14 KR KR1020117004209A patent/KR101653550B1/ko active IP Right Grant
- 2009-09-14 PE PE2011000636A patent/PE20110388A1/es not_active Application Discontinuation
- 2009-09-14 EA EA201100482A patent/EA018603B1/ru not_active IP Right Cessation
- 2009-09-14 DK DK09792493.0T patent/DK2331538T3/da active
- 2009-09-14 ES ES09792493.0T patent/ES2474992T3/es active Active
- 2009-09-14 MX MX2011002828A patent/MX2011002828A/es active IP Right Grant
- 2009-09-14 MY MYPI20111140 patent/MY153093A/en unknown
- 2009-09-14 EP EP09792493.0A patent/EP2331538B1/en active Active
- 2009-09-14 SG SG2013024864A patent/SG189740A1/en unknown
- 2009-09-14 CA CA2737055A patent/CA2737055C/en not_active Expired - Fee Related
- 2009-09-14 PT PT97924930T patent/PT2331538E/pt unknown
- 2009-09-15 AR ARP090103540A patent/AR073298A1/es not_active Application Discontinuation
- 2009-09-15 TW TW98131069A patent/TWI471323B/zh not_active IP Right Cessation
- 2009-09-15 UY UY0001032119A patent/UY32119A/es not_active Application Discontinuation
- 2009-09-15 US US12/559,927 patent/US8232293B2/en active Active
2010
- 2010-12-29 IL IL210345A patent/IL210345A/en active IP Right Grant
2011
- 2011-01-04 ZA ZA2011/00096A patent/ZA201100096B/en unknown
- 2011-03-09 EC EC2011010878A patent/ECSP11010878A/es unknown
- 2011-03-14 MA MA33699A patent/MA32633B1/fr unknown
- 2011-03-16 CO CO11032830A patent/CO6351741A2/es not_active Application Discontinuation
- 2011-03-16 CL CL2011000558A patent/CL2011000558A1/es unknown
- 2011-10-17 HK HK11111031.5A patent/HK1156624A1/xx not_active IP Right Cessation
2012
- 2012-07-03 US US13/541,158 patent/US8362035B2/en active Active
2013
- 2013-12-09 JP JP2013253812A patent/JP2014062116A/ja not_active Withdrawn
2014
- 2014-07-11 CY CY20141100526T patent/CY1115253T1/el unknown
- 2014-07-14 HR HRP20140666AT patent/HRP20140666T1/hr unknown

Also Published As

Publication number	Publication date
ME01831B (me)	2014-12-20
DK2331538T3 (da)	2014-06-02
PE20110388A1 (es)	2011-07-01
AU2009293494A1 (en)	2010-03-25
PL2331538T3 (pl)	2014-09-30
HRP20140666T1 (hr)	2014-10-10
MY153093A (en)	2014-12-31
WO2010033444A1 (en)	2010-03-25
AR073298A1 (es)	2010-10-28
NZ602163A (en)	2013-06-28
ECSP11010878A (es)	2011-07-29
CN102159571B (zh)	2014-10-01
MX2011002828A (es)	2011-04-05
BRPI0918513A2 (pt)	2015-12-01
CN102159571A (zh)	2011-08-17
AU2009293494B2 (en)	2014-04-24
US20120270775A1 (en)	2012-10-25
KR20110059841A (ko)	2011-06-07
US8362035B2 (en)	2013-01-29
ES2474992T3 (es)	2014-07-10
US8232293B2 (en)	2012-07-31
SG189740A1 (en)	2013-05-31
TW201024292A (en)	2010-07-01
CO6351741A2 (es)	2011-12-20
RS53292B (en)	2014-08-29
UY32119A (es)	2010-04-30
WO2010033444A8 (en)	2010-06-17
TWI471323B (zh)	2015-02-01
KR101653550B1 (ko)	2016-09-02
JP2014062116A (ja)	2014-04-10
EA018603B1 (ru)	2013-09-30
HK1156624A1 (en)	2012-06-15
JP2012502910A (ja)	2012-02-02
CY1115253T1 (el)	2017-01-04
CA2737055A1 (en)	2010-03-25
EP2331538B1 (en)	2014-04-16
EP2687526A1 (en)	2014-01-22
US20100093792A1 (en)	2010-04-15
IL210345A (en)	2015-06-30
PT2331538E (pt)	2014-05-12
EA201100482A1 (ru)	2011-10-31
ZA201100096B (en)	2011-09-28
JP5520301B2 (ja)	2014-06-11
NZ591013A (en)	2012-09-28
EP2331538A1 (en)	2011-06-15
CL2011000558A1 (es)	2011-07-15
MA32633B1 (fr)	2011-09-01
PE20130307A1 (es)	2013-03-22
CA2737055C (en)	2016-08-30
IL210345A0 (en)	2011-03-31

Publication	Publication Date	Title
HK1156624A1 (en)	2012-06-15	Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor hcv 2--4--
PT2155200T (pt)	2017-02-21	Forma cristalina de um derivado de carbamoil-ciclohexano
HK1205125A1 (en)	2015-12-11	Polymorphic forms of a macrocyclic inhibitor of hcv hcv
IL221123A (en)	2016-12-29	Powerful polythrocyclic compounds as hcv inhibitors
HK1200440A1 (zh)	2015-08-07	種抑制劑的結晶形式
GB0819182D0 (en)	2008-11-26	Crystalline forms
IL196706A0 (en)	2009-11-18	Crystalline forms of rapamycin analogs
IL221198A0 (en)	2012-10-31	Crystalline salts of a potent hcv inhibitor
HK1164698A1 (en)	2012-09-28	Crystalline forms of genistein
HK1124068A1 (en)	2009-08-07	2-arylindole derivatives as mpges-1 inhibitors
ZA201100999B (en)	2012-05-30	Synthesis of a crystalline silicoaluminophosphate
SI2358676T1 (sl)	2013-01-31	Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
PT2343292E (pt)	2014-11-04	Novo derivado de prostaglandina i2
ZA200903614B (en)	2010-03-31	New crystalline forms
ZA201104319B (en)	2012-03-28	Crystalline forms of a 3-carboxypropyl-aminotetralin compound
AP2013006733A0 (en)	2013-02-28	Solid state forms of a potent HCV inhibitor
IL210777A0 (en)	2011-03-31	Crystalline forms of a pyridine derivative
IL208543A (en)	2016-10-31	History of the eupyrpine peptide as potent inhibitors of encephalin-actopeptidase joint
EP1983997A4 (en)	2009-06-17	CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE
ZA200900740B (en)	2010-05-26	Crystalline forms of rapamycin analogs
HU0800755D0 (en)	2009-03-30	Novel crystalline forms
IL213288A0 (en)	2011-07-31	Crystalline forms
GB0817164D0 (en)	2008-10-29	Crystalline forms